Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform


Out of Business LATEST DEAL TYPE

Developer of drug therapy intended to treat acute bleeding conditions. The company's therapy helps in stabilizing blood clots, increasing anti-bleeding treatment time-window beyond 3 hours, minimizing blood toxicity in the brain and has reduced side effects, enabling physicians to treat their patients in an enhanced way.

Ownership Status
Out of Business
Financing Status
Formerly Accelerator/Incubator backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Primary Office
  • NGT3 VC Technological Incubator
  • P.O. Box 1252
  • Nazareth Illit 17111
  • Israel

+972 00-000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore PamBio’s full profile, request a free trial.

PamBio Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Out of Business 0000 Completed Out of Business
2. Angel (individual) 18-Jul-2016 000 0000 Completed Startup
1. Accelerator/Incubator $3M $3M Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

PamBio Executive Team (4)

Name Title Board
Amos Ofer Ph.D Chief Executive Officer
Nuha Higazi Ph.D Co-Founder & Chief Technology Officer
Abd Higazi MD Co-Founder & Chief Scientific Officer

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »

PamBio Board Members (3)

Name Representing Role Since Contact
Noa Shelach Ph.D PamBio Board Member 000 0000

2 Former Board Members

You’re viewing 1 of 3 board members. Get the full list »